Over 50 years of research and 70+ published studies support its safety at therapeutic doses
While full-dose regimens are more effective for significant weight control, microdosing may still support appetite suppression and gradual results
A trend was observed between GSH levels and anxiety symptom scores (Spearmans rho = 0.14, p = 0.0529) and between GSHc levels and anxiety symptom scores (Spearmans rho = 0.14, p = 0.0559)
While generally safe, some may experience allergic reactions, abdominal pain, or light-headedness
Causality and associated mechanisms are difficult to establish as ED and these metabolic conditions also share risk factors such as age, hypertension, diabetes, insulin resistance, smoking, and increased BMI